



Endologix
Investor Relations Department
2 Musick
Irvine, CA 92618
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ELGX

Last Trade:	5.26
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	-0.02 ↓ (-0.379%)
Day Range	5.19 - 5.48
52-Week Range	4.08 - 7.91
Volume	553,323

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

Stock Performance



Press Releases [\[View all \]](#)

Nov 14, 2017
[Endologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare Conference](#)

Nov 7, 2017
[Endologix Reports Third Quarter 2017 Financial Results](#)

Nov 1, 2017
[Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Oct 26, 2017
[Endologix, Inc. to Present at the Stifel 2017 Healthcare Conference](#)

Oct 19, 2017
[Endologix Appoints John Onopchenko as Chief Operating Officer](#)

Upcoming Events [\[View all \]](#)

Nov 29, 2017 2:50 PM ET
[Piper Jaffray 29th Annual Healthcare Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 1, 2017
[Annual Report \(10-K\)](#)

May 1, 2017
[Proxy Statement \(DEF 14A\)](#)

Nov 7, 2017
[Quarterly Report \(10-Q\)](#)

Aug 4, 2017
[Quarterly Report \(10-Q\)](#)

May 5, 2017
[Quarterly Report \(10-Q\)](#)